Updated on 11 September 2026
GCS HUGO, in integrated academic health network of University Hospitals in Western France
European Coordinator - GCS HUGO at GCS HUGO
Angers, France
About
In France, large teaching hospitals – known as University Hospitals (Centres Hospitaliers Universitaires, or CHU) – have a threefold mission:
-
delivering patient care, including highly specialized and tertiary services,
-
medical education and training,
-
conducting biomedical research and fostering innovation.
A distinctive feature of the French University Hospital model is the close integration of academic and clinical activities. Teaching and research facilities are closely linked with hospital infrastructures within the same institution, creating an environment that fosters collaboration among healthcare professionals, researchers and educators.
HUGO builds on this model by extending collaboration beyond individual institutions. Its philosophy is to strengthen the three core missions of university hospitals—care, education and research—through large-scale, structuring initiatives that benefit from shared investment, pooled expertise and economies of scale. By working collectively, HUGO’s members can develop ambitious infrastructures, research programmes, training initiatives and innovation projects that would be more difficult to achieve independently.
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-08 Towards Artificial General Intelligence (AGI) for healthcare
Type
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
Clinical Studies for Horizon Europe Cluster Health 2027
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Juan Abolafia
Head EU office at Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer
Barcelona, Spain
Project cooperation
Smart Workflow Automation for Clinical Trial Management
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
George Nikolaidis
CEO at Ergobyte Informatics S.A.
Thessaloniki, Greece
Project cooperation
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Wolfgang Fecke
Executive Director at Association of European Cancer Leagues (ECL)
Brussels, Belgium